TScan Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $27.32M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | $1.10M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | Before market open | $1.00M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 4, 2026 | Before market open | $2.60M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $2.50M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | $3.10M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | $2.20M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 5, 2025 | Before market open | $700.00K | $-0.30 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $1.00M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 6, 2024 | Before market open | – | – | – |
Press releases
Announcements TScan Therapeutics filed with the SEC
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell
Exit or restructuring costs · Listing notice · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding TScan
Exit or restructuring costs · Listing notice · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Data from Cohort C of the Phase 1
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Investor call November 3, 2025 Exhibit
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Refinances Existing Convertible Debt Facility
Material agreement · Agreement terminated · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA Phase
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
KOL Event December 10, 2024 Exhibit
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Announces Launch of $125 million Proposed
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
accompanying discussion contain forward-looking TScan’s plans relating to developing and commercializing its TCR-T therapy statements within the meaning of the Private Securities Litigation Reform Act of candidates, if approved, including
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert
Other events · EX-99.1 to Form 8-K
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Presents Initial Phase 1 Clinical Results on
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TScan Therapeutics KOL event: Dec. 11,
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
TScan Therapeutics Announces Transition of Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
TScan Therapeutics Announces Launch of Proposed Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
TScan Therapeutics Announces Pricing of $140 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on
Other events · EX-99.1 to Form 8-K
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99 to Form 8-K
AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN’S DISEASE
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
TSCAN THERAPEUTICS ANNOUNCES CEO TRANSITION
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
Results of operations · EX-99 to Form 8-K